{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:24:16Z","timestamp":1790821456579,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.eprac.2021.06.012","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:35:47Z","timestamp":1628602547000},"page":"956-965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Kevin C.J.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.eprac.2021.06.012_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9996","key":"10.1016\/j.eprac.2021.06.012_bib2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.012_bib3","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2021.06.012_bib4","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2021.06.012_bib5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing\u2019s syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2021.06.012_bib6","doi-asserted-by":"crossref","first-page":"A521","DOI":"10.1210\/jendso\/bvab048.1063","article-title":"Long-term control of urinary free cortisol with osilodrostat in patients with Cushing\u2019s disease: final results from the LINC 2 study","volume":"5","author":"Fleseriu","year":"2021","journal-title":"J Endocr Soc"},{"issue":"2","key":"10.1016\/j.eprac.2021.06.012_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2021.06.012_bib8","doi-asserted-by":"crossref","first-page":"A516","DOI":"10.1210\/jendso\/bvab048.1055","article-title":"Osilodrostat is an effective and well-tolerated treatment for Cushing\u2019s disease: results from a Phase III study with an upfront, randomized, double-blind, placebo-controlled phase (LINC 4)","volume":"5","author":"Gadelha","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.eprac.2021.06.012_bib9","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fendo.2020.00648","article-title":"Medical treatment of Cushing's disease: an overview of the current and recent clinical trials","volume":"11","author":"Pivonello","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.eprac.2021.06.012_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2021.06.012_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ecl.2020.05.003","article-title":"Advances in the medical treatment of Cushing disease","volume":"49","author":"Tritos","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"10.1016\/j.eprac.2021.06.012_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing's disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.eprac.2021.06.012_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eprac.2021.06.012_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-017-0497-0","article-title":"Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults","volume":"37","author":"Armani","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.012_bib15","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1210\/jc.2019-00217","article-title":"Osilodrostat Is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in\u00a0vitro study","volume":"104","author":"Creemers","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.012_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-014-0340-9","article-title":"Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects","volume":"12","author":"M\u00e9nard","year":"2014","journal-title":"J\u00a0Transl Med"},{"issue":"18","key":"10.1016\/j.eprac.2021.06.012_bib17","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.012_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.eprac.2021.06.012_bib19","first-page":"296","article-title":"Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"19","author":"Wang","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.eprac.2021.06.012_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-020-01277-0","article-title":"Osilodrostat: first approval","volume":"80","author":"Duggan","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.012_bib23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1060028020968808","article-title":"Osilodrostat: a novel steroidogenesis inhibitor to treat Cushing\u2019s disease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.06.012_bib24","first-page":"SAT","article-title":"SAT-443 Osilodrostat has no clinically relevant effect on the pharmacokinetic (PK) profile of a monophasic oral contraceptive in healthy females receiving cortisol replacement therapy","volume":"3","author":"Breitschaft","year":"2019","journal-title":"J\u00a0Endocr Soc"},{"issue":"10S","key":"10.1016\/j.eprac.2021.06.012_bib25","doi-asserted-by":"crossref","first-page":"A61.e583","DOI":"10.1016\/S0735-1097(10)60584-0","article-title":"Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy subjects","volume":"55","author":"M\u00e9nard","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.eprac.2021.06.012_bib26","author":"Recordati Rare Disease"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.012_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1258\/acb.2011.011014","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11beta-hydroxylase inhibitor metyrapone","volume":"48","author":"Monaghan","year":"2011","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"10.1016\/j.eprac.2021.06.012_bib28","doi-asserted-by":"crossref","first-page":"bvab022","DOI":"10.1210\/jendso\/bvab022","article-title":"New cutoffs for the biochemical diagnosis of adrenal insufficiency after ACTH stimulation using specific cortisol assays","volume":"5","author":"Javorsky","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"5","key":"10.1016\/j.eprac.2021.06.012_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/2042098612454283","article-title":"Drug-induced QT interval prolongation: mechanisms and clinical management","volume":"3","author":"Nachimuthu","year":"2012","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"10.1016\/j.eprac.2021.06.012_bib31","doi-asserted-by":"crossref","first-page":"L7","DOI":"10.1530\/EJE-20-0557","article-title":"Efficacy and tolerance of osilodrostat in patients with severe Cushing's syndrome due to non-pituitary cancers","volume":"183","author":"Haissaguerre","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2021.06.012_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.012_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2021.06.012_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11102-020-01097-1","article-title":"Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing\u2019s disease","volume":"24","author":"Fontaine-Sylvestre","year":"2021","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.eprac.2021.06.012_bib35","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.tem.2020.04.004","article-title":"The immune system in Cushing's syndrome","volume":"31","author":"Hasenmajer","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.eprac.2021.06.012_bib36","first-page":"1","article-title":"Glucocorticoid excess and COVID-19 disease","author":"Guarnotta","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.012_bib37","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-20-0352","article-title":"Endocrinology in the time of COVID-19: management of Cushing's syndrome","volume":"183","author":"Newell-Price","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.012_bib38","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S2213-8587(20)30215-1","article-title":"COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.012_bib39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4158\/EP-2020-0308","article-title":"Important management considerations in patients with pituitary disorders during the time of the COVID-19 pandemic","volume":"26","author":"Yuen","year":"2020","journal-title":"Endocr Pract"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21011071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21011071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:10:17Z","timestamp":1761516617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X21011071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1530891X21011071"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2021.06.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2021.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}